Across TCGA pan-cancer cohorts, CCDC196 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CCDC196 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CCDC196 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC196 expression acts as an unfavorable survival marker.

LIHC and SARC are the cancer types where CCDC196 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.053	0.553	<.001	12	view →
SARC	OS	Median	All	0.201	0.766	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CCDC196 tumor-vs-normal RNA expression · all CCDC196 data types